BeiGene has opened its flagship U.S. facility in Hopewell, N.J., featuring state-of-the-art biologics manufacturing and a clinical R&D centre to bolster its global oncology growth

New Jersey’s robust biopharmaceutical environment, skilled workforce, and connectivity support BeiGene’s mission to develop affordable cancer treatments

The $800 million investment at the 42-acre Princeton West Innovation Campus will also support the production and clinical research of ADCs, crucial for targeted cancer therapies

This facility enhances BeiGene’s manufacturing and development capabilities, strengthens BeiGene’s commitment to developing next-generation ADCs